Combined anti‑HER2 and hormonal treatment in a patient with HR+HER2+ clear‑cell uterine carcinoma: A case report

Gordeeva,Olga O.; Meshcheryakova,Lyudmila A.; Karseladze,Apollon I.; Meshcheryakova,Nadezhda A.; Meshcheryakov,Andrey A.

doi:10.3892/mco.2020.2181

January-2021 Volume 14 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2021 Volume 14 Issue 1

Full Size Image

Case Report Open Access

Combined anti‑HER2 and hormonal treatment in a patient with HR+HER2+ clear‑cell uterine carcinoma: A case report

Authors:
- Olga O. Gordeeva
- Lyudmila A. Meshcheryakova
- Apollon I. Karseladze
- Nadezhda A. Meshcheryakova
- Andrey A. Meshcheryakov
View Affiliations / Copyright

Affiliations: Department of Chemotherapy No. 3, FSBI ‘N.N. Blokhin National Medical Research Center of Oncology’ of The Ministry of Health of Russian Federation, Moscow 115478, Russia, Department of Oncogynecology, FSBI ‘N.N. Blokhin National Medical Research Center of Oncology’ of The Ministry of Health of Russian Federation, Moscow 115478, Russia, Department of Pathology, FSBI ‘N.N. Blokhin National Medical Research Center of Oncology’ of The Ministry of Health of Russian Federation, Moscow 115478, Russia, Department of Radiology (PET/CT Diagnostic), FSBI ‘N.N. Blokhin National Medical Research Center of Oncology’ of The Ministry of Health of Russian Federation, Moscow 115478, Russia

Copyright: © Gordeeva et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 19
|
Published online on: November 27, 2020

https://doi.org/10.3892/mco.2020.2181
Expand metrics +

Abstract

Clear‑cell carcinoma (CCC) of the uterus is an aggressive disease. Current international guidelines on the treatment of uterine carcinomas predominantly cover cancer with endometrioid histology, and clinicians tend to use the same approach for patients with non‑endometrioid histology due to the absence of separate guidelines for these rare tumor types. At present, molecular analysis enables the assessment of novel and non‑standard treatment options based on the individual characteristics of a tumor. The present report presents a clinical case of successful treatment of a patient with clear cell uterine carcinoma with HER2 and ER expression. Non‑toxic targeted treatment was used based on immunohistochemistry (IHC) data. The patient received anti‑HER2 and hormonal treatment and demonstrated an excellent response. The follow‑up period was 47 months and the patient remained stable during treatment without significant toxicity. Therefore, this approach demonstrated the potential for selecting highly‑specific therapy for rare tumors, which lack distinct recommendations for their treatment.

View Figures

View References

1	Jones NL, Xiu J, Chatterjee-Paer S, de Meritens AB, Burke WM, Tergas AI, Wright JD and Hou JY: Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. Int J Cancer. 140:1396–1404. 2017.PubMed/NCBI View Article : Google Scholar
2	Glasspool RM and McNeish IA: Clear cell carcinoma of ovary and uterus. Curr Oncol Rep. 15:566–572. 2013.PubMed/NCBI View Article : Google Scholar
3	Abu-Rustum NR, Yashar CM, Bradley K, et al: NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms. Version 4, 2019.
4	Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z and Kurzrock R: HER2 expression status in diverse cancers: Review of results from 37,992 patients. Cancer Metastasis Rev. 34:157–164. 2015.PubMed/NCBI View Article : Google Scholar
5	Halle MK, Tangen IL, Berg HF, Hoivik EA, Mauland KK, Kusonmano K, Berg A, Hurtado A, Kalland KH, Øyan AM, et al: HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. Br J Cancer. 118:378–387. 2018.PubMed/NCBI View Article : Google Scholar
6	Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, et al: Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 36:2044–2051. 2018.PubMed/NCBI View Article : Google Scholar
7	Lindahl B, Persson J, Ranstam J and Willén R: Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma. Anticancer Res. 30:3727–3730. 2010.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Combined anti‑HER2 and hormonal treatment in a patient with HR+HER2+ clear‑cell uterine carcinoma: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles